Sustained serological and complete responses in HBeAg-positive patients treated with Peginterferon alfa-2b: a 6-year long-term follow-up of a multicenter, randomized, controlled trial in China

BACKGROUND: Pegylated interferon (PEG-IFN) alfa-2b is recommended for chronic hepatitis B (CHB). We aimed to investigate the sustainability of off-treatment responses among Chinese HBeAg-positive CHB patients treated with PEG-IFN alfa-2b from a randomized trial. METHODS: Eligible Chinese patients (n...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:BMC Gastroenterol
Autors principals: Sun, Jian, Ding, Huiguo, Chen, Guofeng, Wang, Guiqiang, Wei, Lai, Zhang, Jiming, Xie, Qing, Wan, Mobin, Tang, Hong, Chen, Shijun, Gao, Zhiliang, Wang, Yuming, Zhang, Dazhi, Huang, Wenxiang, Sheng, Jifang, Ning, Qin, Yang, Dongliang, Lu, Jian, Pan, Chen, Yang, Yuxiu, Wang, Jue, Sun, Chuanzhen, Wang, Qixin, Hou, Jinlin
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2019
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6498535/
https://ncbi.nlm.nih.gov/pubmed/31046700
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12876-019-0981-5
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars